BioMarin Announces FDA Acceptance Of Regulatory Application For Hemophilia Gene Therapy BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) said the FDA has accepted for Priority Review its BLA for its investigational AAV5  gene therapy  valoctoocogene roxaparvovec for adults with hemophilia A. Taro Recalls 2 Lots of Seizure Drug Taro Pharma said it is voluntarily recalling two lots of seizure drug Phenytoin oral suspension USP, 125 mg/5mL, both in 237 mL bottles, to the consumer level.Akari Therapeutics PLC (NASDAQ: AKTX) said it has entered into definitive agreements with certain accredited investors, includingÂ Chairman Dr. Ray Prudo, to raise gross proceeds of about $6 million through the private placement of shares.